News Overview

Not intended for U.S. and UK media:
Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA for the Treatment of Venous Thromboembolism (VTE) and Long-Term Prevention of Recurrent VTE

Management Board Chairman Dr. Marijn Dekkers at the Annual Stockholders’ Meeting of Bayer AG:
Bayer has great potential for the future too

1st quarter of 2012:
Encouraging start to the year for Bayer

Not intended for US or UK use - Aesthetic medicine:
Positive results from two European Phase III trials with ATX-101 demonstrate reduction of submental fat

New fungicidal seed treatment product for oilseed rape:
First approval worldwide for EverGol™ in seed treatment

Not intended for U.S. and UK Media: Prevention of Venous Blood Clots after Elective Total Hip or Knee Replacement Surgery:
Real-World Experience Reaffirms Bayer’s Xarelto® (Rivaroxaban) as Safe and Effective in Protecting Patients Against Blood Clots

Innovative breeding approach creates new opportunities for sugar beet growers:
Bayer CropScience and KWS SAAT AG co-develop herbicide-tolerant sugar beet

Not intended for U.S. and UK media
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE

Not intended for U.S. and U.K. Media
Phase III Trial of Regorafenib in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Meets Primary Endpoint of Improving Progression-Free Survival

Not intended for U.S. and UK Media - Treatment of Pulmonary Embolism (PE):
Bayer’s Xarelto® (Rivaroxaban) Proven Effective in Treating Patients with Pulmonary Embolism and in Preventing Recurrent Venous Blood Clots in Phase III EINSTEIN-PE Study

Not intended for UK and US Media: Treatment of Pulmonary Embolism (PE):
Results of the Phase III EINSTEIN-PE Study with Bayer’s Xarelto® (Rivaroxaban) to be Presented in Late-Breaking Clinical Trials Session at ACC 2012

“Meet Management” investor conference:
Bayer sets ambitious targets for 2014

Not intended for U.S. and UK Media
EYLEA® (aflibercept) Injection approved for the Treatment of Wet Age-Related Macular Degeneration in Australia

Financial and innovation targets for 2011 achieved
Bayer: sales and EBIT at record levels

Not intended for U.S. and UK Media: Secondary Prevention of Acute Coronary Syndrome (ACS):
Bayer’s Xarelto® (Rivaroxaban) Granted Priority Review by US FDA to Prevent Secondary Cardiovascular Events in Patients with ACS

Elections to the Supervisory Board to be held at the Annual Stockholders’ Meeting on April 27, 2012
Werner Wenning to be proposed as Chairman of the Supervisory Board of Bayer AG

Not intended for U.S. and UK Media
Positive One Year results From Phase 3 Study in Central Retinal Vein Occlusion of VEGF Trap-Eye

Not intended for UK and US Media - Stroke Prevention in Patients with Atrial Fibrillation:
Bayer’s Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation

Not intended for U.S. and UK Media (LBA #385) - Results of pivotal Phase III study in patients with metastatic colorectal cancer:
Positive Phase III Data on Bayer’s Investigational Drug Regorafenib Show Significant Increase in Overall Survival